The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
The Life Raft Group partnered with Dr. Michael Wagner of the University of Washington to present “The Importance of Biomarker Testing” to GIST patients and caregivers on August 12th, 2022.
The Life Raft Group is currently conducting a tissue testing initiative for GIST patients to receive FREE Next-Generation Sequencing (NGS) Testing!
The European Cancer Patient Coalition (ECPC) has published an e-module on Genetics and Genomics Testing in English, German, French, Italian, and Spanish.
In this webinar, there were case study presentations from three top sarcoma institutions that demonstrate the value of biomarker testing. A Question & Answer session followed the presentations.
This video is about understanding the role of mutations and biomarker testing in GIST. Knowing the driving force behind each individual’s tumors is not just important, it is critical in determining the most effective treatment for your mutation.
The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.
So far in 2021, our 'It's Time' campaign has emphasized twelve important points concerning biomarker testing and the important role it plays in a GIST patient's journey. We will keep the momentum going with patient stories, webinars, and resource materials.
Biomarker testing is an opportunity to improve and optimize treatment. In this post, GISTer Bill Borwegen shares his story and we share how you can help save lives.